This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAbout OCTAGAM 10%EfficacyEfficacyDMcITPSafety & TolerabilitySafety & TolerabilityDMcITPDosing & Infusion RatesDosing & Infusion Rates DMcITPSupportSupportMaterialsVideosPfizer OCTAGAM Co-Pay ProgramPfizer IGuide™Ig CompanionFrequently asked questionsRequest a representative

Coverage

Prescribing Information, including BOXED WARNINGIndicationsOCTAGAM 5%Patient Site
EfficacyOCTAGAM 10% [Immune Globulin Intravenous (Human)] liquid

cITP study designs

cITP primary endpoint

cITP secondary endpoints

Efficacy, safety, and tolerability of OCTAGAM 10% were evaluated in a clinical study of adult patients with cITP

Prospective, open-label, single-arm, multicenter study1,2

One patient was incorrectly enrolled in the study and was excluded from all efficacy analyses.
See primary efficacy endpoint data from the cITP study 
Loading
References:Octagam 10%. Prescribing information. Octapharma USA Inc.; 2022.Data on file. Octapharma USA Inc.
Primary efficacy results for OCTAGAM 10% from the cITP clinical study

The majority of patients met the primary endpoint of clinical response as measured by a rise in platelet count1

See secondary efficacy endpoint data from the cITP study
Loading
Reference:Octagam 10%. Prescribing information. Octapharma USA Inc.; 2022.
Secondary endpoint results for OCTAGAM 10% from the cITP clinical study 

Secondary endpoint results support the efficacy of OCTAGAM 10%1

Analyzed for 54 patients who achieved a response within 7 days after the first infusion.
Reference:Octagam 10%. Prescribing information. Octapharma USA Inc.; 2022.
Efficacy cITP safety and tolerability data for OCTAGAM 10%

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

 Review data Loading cITP dosing and infusion rates for OCTAGAM 10% See details Loading

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-OTG-USA-0273

Indications and Usage

OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.

Please click here for Full Prescribing Information, including BOXED WARNING.

Indications and Usage OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults. Please click here for Full Prescribing Information, including BOXED WARNING.
IMPORTANT SAFETY
INFORMATION WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IgIV) products, including OCTAGAM 10% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IgIV products, including OCTAGAM 10% liquid. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IgIV products containing sucrose. OCTAGAM 10% liquid does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer OCTAGAM 10% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Dosing and Administration Patients with dermatomyositis are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min. ContraindicationsOCTAGAM 10% liquid is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.Warnings and PrecautionsOCTAGAM 10% liquid may cause hypersensitivity in patients with a corn allergy. OCTAGAM 10% liquid contains maltose, which is derived from corn. Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure. Falsely elevated blood glucose readings may occur during and after the infusion of OCTAGAM 10% liquid with testing by some glucometers and test strip systems. Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving OCTAGAM 10% liquid. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to treatment with OCTAGAM 10% liquid. Risk factors for hemolysis include high doses and non–O-blood group. Closely monitor patients for hemolysis and hemolytic anemia. Aseptic meningitis syndrome may occur in patients receiving OCTAGAM 10% liquid, especially with high doses or rapid infusion. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). OCTAGAM 10% liquid is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent. Adverse Reactions cITP - The most common adverse reactions reported in >5% of study subjects were headache, fever, and increased heart rate. DM - The most common adverse reactions reported in >5% of study subjects were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusion site reactions.You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.OCTAGAM® is a registered trademark of Octapharma AG.Please click here for Full Prescribing Information, including BOXED WARNING.INDICATIONS AND USAGEOCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.